Occupational learning tool developer NovoEd, based on research at Stanford, has been bought by Devonshire Investors after raising $4.8m of series A capital in 2014.
UC Berkeley’s SkyDeck accelerator has secured an exit as schoolwork assessment technology developer Gradescope was acquired by Turnitin.
The UCL Technology Fund is in line for an exit from gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.
Sutro Biopharma, an immunotherapy developer commercialising technology created at Stanford University, has floated on the Nasdaq Global Market.
Principia Biopharma, whose drug discovery platform is based on research at UCSF, has completed a $122m initial public offering after underwriters exercised their greenshoe option.
Karolinska Development has celebrated an exit as Umeå spinout Asarina Pharma went public in Sweden after raising $16.3m in its initial public offering.
Educational content creation platform Acrobatiq spun out from Carnegie Mellon University in 2015 and had been backed by the university's Carnegie Innovations division.
Softgarden, a spinout of Saarland University, has been acquired for Investcorp Technology Partners for an undisclosed sum.
A month after Sutro closed an $85.4m series E round, the cancer drug developer, based on research at Stanford, has filed for a $75m initial public offering.
Epigenomics services provider Epinomics, co-founded by Stanford University faculty and alumni, has been bought by 10x Genomics in a transaction which enables StartX to exit.